Kentucky Equine Council Hears Pitch for Stem Cell Trial

POSTED ON  |  15-09-2020

Equiflow
In the midst of a phaseout of the diuretic Lasix in some racing jurisdictions, options for racehorses who bleed in their lungs might not be limited to a simple diet of hay, oats, and water. Speaking during a video-conference meeting of the Kentucky Equine Drug Research Council Sept. 11, representatives of the regenerative medicine company ReCellerate pitched the council for a clinical trial of the company's Equiflow stem cell-derived treatment. Equiflow has shown early indications of controlling exercise induced pulmonary hemorrhage, the company claims.

Though the council did not take action, seeking more specifics on a possible trial, information on the program and its initial returns were presented. The product, a concentrated protein serum administered with a nebulizer, is estimated by the company to be two to three years away from receiving conditional approval from the Food and Drug Administration. ReCellerate says it repairs capillary damage by regenerating and strengthening the ruptured blood vessel walls, which they say can stop or slow the regular occurrence of bleeding.

Not a race-day medication, its recommended treatment falls 7-10 days before a race. More severe bleeding may require multiple treatments. Its cost was not discussed. An earlier study offered by ReCellerate said Equiflow had been trialed on 18 horses at Middleburg Training Center in Virginia. Of this sample, company officials spotlighted the success of Celtic Katie, who won the Geisha Stakes at Pimlico Race Course in 2014 for owner Lewis Family Racing Stable and trainer Christopher Grove. According to the company, she was a filly who would bleed after being given Lasix for morning workouts.

© 2015 IGSRV All rights reserved.